1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 4-(morpholine-4-sulfonyl)-benzylamide | 1453173-74-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 4-(morpholine-4-sulfonyl)-benzylamide
• 英文别名: N-(4-(morpholinosulfonyl)benzyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxamide；N-[(4-morpholin-4-ylsulfonylphenyl)methyl]-1H-pyrrolo[3,2-c]pyridine-2-carboxamide
• CAS: 1453173-74-4
• 化学式: C₁₉H₂₀N₄O₄S
• 分子量: 400.458
• InChiKey: QWQIONDXHVTLHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  113
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-氮杂吲哚-2-甲酸 、 4-(4-磺酰基吗啉)-苄胺盐酸盐 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 1H-pyrrolo[3,2-c]pyridine-2-carboxylic acid 4-(morpholine-4-sulfonyl)-benzylamide
  参考文献：
  名称：

  Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility

  摘要：

  Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering cLogD(7.4) was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.026

文献信息

• AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES
  申请人：Bair Kenneth W.

  公开号：US20150104384A1

  公开（公告）日：2015-04-16

  The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些酰胺基苯基亚砜和砜化合物，包括这些化合物的药物组合物和使用这些化合物的治疗方法。
• Amido-benzyl sulfone and sulfoxide derivates
  申请人：Forma TM, LLC

  公开号：US10696692B2

  公开（公告）日：2020-06-30

  The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

  本发明涉及某些氨基苄基亚砜和砜化合物、包含此类化合物的药物组合物以及使用此类化合物进行治疗的方法。
• [EN] METHODS OF USING ANTAGONISTS OF NAD BIOSYNTHESIS FROM NICOTINAMIDE<br/>[FR] PROCÉDÉS D'UTILISATION D'ANTAGONISTES DE BIOSYNTHÈSE DE NICOTINAMIDE ADÉNINE DINUCLÉOTIDE À PARTIR DE NICOTINAMIDE
  申请人：GENENTECH INC

  公开号：WO2013170191A1

  公开（公告）日：2013-11-14

  Provided herein are NAD biosynthesis from nicotinamide antagonists (e.g., Nampt antagonists and/or NMNAT antagonists) and methods of using the same.
• Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility
  作者：Mark Zak、Bianca M. Liederer、Deepak Sampath、Po-wai Yuen、Kenneth W. Bair、Timm Baumeister、Alexandre J. Buckmelter、Karl H. Clodfelter、Eric Cheng、Lisa Crocker、Bang Fu、Bingsong Han、Guangkun Li、Yen-Ching Ho、Jian Lin、Xiongcai Liu、Justin Ly、Thomas O’Brien、Dominic J. Reynolds、Nicholas Skelton、Chase C. Smith、Suzanne Tay、Weiru Wang、Zhongguo Wang、Yang Xiao、Lei Zhang、Guiling Zhao、Xiaozhang Zheng、Peter S. Dragovich

  DOI：10.1016/j.bmcl.2014.12.026

  日期：2015.2

  Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likely source of the TDI signal, and replacement with other bicyclic systems was found to reduce or eliminate the TDI finding. A strategy of reducing the number of aromatic rings and/or lowering cLogD(7.4) was then employed to significantly improve aqueous solubility. These efforts culminated in the discovery of 42, a compound with no evidence of TDI, improved aqueous solubility, and robust efficacy in tumor xenograft studies. (C) 2014 Elsevier Ltd. All rights reserved.